Approximately 50% of patients with metastatic melanoma harbor somatic mutations in the B-Raf proto-oncogene (BRAF) [33], which leads to constitutive activation of the BRAF oncoprotein [34,35]. This evidence concerns the gene BRAF and metastatic melanoma.